Pulse Biosciences (PLSE) vs. Reshape Lifesciences (RSLS) Head-To-Head Contrast

Pulse Biosciences (NASDAQ: PLSE) and Reshape Lifesciences (NASDAQ:RSLS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Pulse Biosciences and Reshape Lifesciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences 0 0 0 0 N/A
Reshape Lifesciences 0 0 1 0 3.00

Reshape Lifesciences has a consensus price target of $11.00, suggesting a potential upside of 566.67%. Given Reshape Lifesciences’ higher possible upside, analysts plainly believe Reshape Lifesciences is more favorable than Pulse Biosciences.


This table compares Pulse Biosciences and Reshape Lifesciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pulse Biosciences N/A -62.10% -57.47%
Reshape Lifesciences -4,509.61% -104.23% -90.59%

Valuation & Earnings

This table compares Pulse Biosciences and Reshape Lifesciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pulse Biosciences N/A N/A -$9.51 million ($1.40) -15.71
Reshape Lifesciences $790,000.00 62.57 -$23.36 million ($5.90) -0.28

Pulse Biosciences has higher earnings, but lower revenue than Reshape Lifesciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Reshape Lifesciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

9.3% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 0.5% of Reshape Lifesciences shares are owned by institutional investors. 6.7% of Pulse Biosciences shares are owned by company insiders. Comparatively, 26.4% of Reshape Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


Pulse Biosciences beats Reshape Lifesciences on 6 of the 11 factors compared between the two stocks.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

Reshape Lifesciences Company Profile

ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply